Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors

    Moderna Therapeutics Appoints Theo Melas-Kyriazi to Board of Directors

PR Newswire

CAMBRIDGE, Mass., Dec. 17, 2013

CAMBRIDGE, Mass., Dec. 17, 2013 /PRNewswire/ --Moderna Therapeutics, the
pioneer in developing messenger RNA (mRNA) Therapeutics™, a revolutionary new
treatment modality to enable the in vivo production of therapeutic proteins,
announced today that Theo Melas-Kyriazi, CFO of Levitronix Technologies LLC
and a director of Valeant Pharmaceuticals International (NYSE: VRX and TSX:
VRX) has joined Moderna's board of directors.

Melas-Kyriazi brings extensive financial and executive leadership experience
to Moderna, having previously served as CFO and vice president of corporate
strategy for Thermo Electron Corporation (now Thermo Fisher Scientific). He
also has experience as CEO of Thermo Spectra Corporation, a former subsidiary
of Thermo Electron, and as a board member and investor in several early stage
health sciences companies. Melas-Kyriazi joins Moderna's board as the company
embarks on the next phase of its growth strategy focused on clinical
development and building the world's leading mRNA platform.

"I am thrilled that Theo is joining the Moderna board of directors. He brings
important expertise and skill to the company as we scale up to build the
leader in mRNA therapeutics," said Stephane Bancel, president and founding CEO
of Moderna. "With his experience as CFO of Thermo Electron, a large, public
life sciences company, and as a director of Valeant for the last ten years,
during a period of extraordinary growth, he will be a tremendous asset to help
guide Moderna's future growth."

"I am truly excited to be joining the board of Moderna, a company with
tremendous potential to transform drug development," said Melas-Kyriazi.
"Moderna's novel platform and ambitious vision stands out among early
biotechnology leaders, and I look forward to helping the company deliver on
its mission to improve the lives of patients across a broad range of
diseases."

About Moderna Therapeutics

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo
drug modality that produces human proteins or antibodies inside patient cells,
which are in turn active intracellularly or secreted. This breakthrough
platform addresses currently undruggable targets and offers a superior
alternative to existing drug modalities for a wide range of disease
conditions. Moderna has developed a broad intellectual property estate,
including more than 200 patent applications with more than 10,000 claims
ranging from novel nucleotide chemistries to specific drug compositions. The
company plans to develop and commercialize its innovative mRNA drugs—initially
for rare diseases and oncology—while partnering drug candidates in other
therapeutic areas in order to rapidly deliver this innovation to patients.
Moderna is a privately held company based in Cambridge, Massachusetts. Visit
www.modernatx.com to learn more.

For information contact:
Maria Favorito
617-761-6720
Maria.Favorito@fkhealth.com

SOURCE Moderna Therapeutics

Website: http://www.modernatx.com